NO20061944L - Ny assosiasjon av et antiaterotrombotisk middel og et antiplateaggregerede middel - Google Patents

Ny assosiasjon av et antiaterotrombotisk middel og et antiplateaggregerede middel

Info

Publication number
NO20061944L
NO20061944L NO20061944A NO20061944A NO20061944L NO 20061944 L NO20061944 L NO 20061944L NO 20061944 A NO20061944 A NO 20061944A NO 20061944 A NO20061944 A NO 20061944A NO 20061944 L NO20061944 L NO 20061944L
Authority
NO
Norway
Prior art keywords
new association
agent
platelet aggregate
atherothrombotic
atherothrombotic agent
Prior art date
Application number
NO20061944A
Other languages
English (en)
Inventor
Laure Cloarec-Blanchard
Stefano Corda
Laurence Lerond
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20061944L publication Critical patent/NO20061944L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Den foreliggende oppfirmelse vedrører en ny assosiasjon bestående av et antiaterotrombotisk middel og et antiplateaggregerende middel. Oppfirmelsen vedrører også medikamenter.
NO20061944A 2003-10-03 2006-05-02 Ny assosiasjon av et antiaterotrombotisk middel og et antiplateaggregerede middel NO20061944L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0311595A FR2860436B1 (fr) 2003-10-03 2003-10-03 Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
PCT/FR2004/002489 WO2005032533A1 (fr) 2003-10-03 2004-10-01 Nouvelle association d'un anti-atherothrombotique et d’un antiagregant plaquettaire

Publications (1)

Publication Number Publication Date
NO20061944L true NO20061944L (no) 2006-05-02

Family

ID=34307392

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061944A NO20061944L (no) 2003-10-03 2006-05-02 Ny assosiasjon av et antiaterotrombotisk middel og et antiplateaggregerede middel

Country Status (28)

Country Link
US (2) US20070054934A1 (no)
EP (1) EP1677779B1 (no)
JP (1) JP2007507475A (no)
KR (1) KR100782246B1 (no)
CN (1) CN100453075C (no)
AR (1) AR046043A1 (no)
AT (1) ATE409033T1 (no)
AU (1) AU2004277734B2 (no)
BR (1) BRPI0415043A (no)
CA (1) CA2540062A1 (no)
CY (1) CY1108388T1 (no)
DE (1) DE602004016762D1 (no)
DK (1) DK1677779T3 (no)
EA (1) EA009418B1 (no)
ES (1) ES2314457T3 (no)
FR (1) FR2860436B1 (no)
GE (1) GEP20084546B (no)
HR (1) HRP20080546T3 (no)
MA (1) MA28081A1 (no)
MX (1) MXPA06003713A (no)
MY (1) MY137953A (no)
NO (1) NO20061944L (no)
NZ (1) NZ545988A (no)
PL (1) PL1677779T3 (no)
PT (1) PT1677779E (no)
SI (1) SI1677779T1 (no)
UA (1) UA80220C2 (no)
WO (1) WO2005032533A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05014086A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antiagregantes plaquetarios combinadas para su uso en el tratamiento y prevencion de eventos vasculares de origen isquemico.
FR2899473B1 (fr) * 2006-04-07 2008-06-13 Servier Lab Utilisation d'un compose anti-atherothrombotique pour l'obtention de medicaments destines au traitement des troubles vasculaires
EA020531B1 (ru) * 2007-04-13 2014-11-28 Милленниум Фармасьютикалз, Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИКОАГУЛИРУЮЩЕГО СРЕДСТВА С СОЕДИНЕНИЕМ, КОТОРОЕ ДЕЙСТВУЕТ КАК ИНГИБИТОР ФАКТОРА Ха
FR2920772B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711139B1 (fr) * 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination

Also Published As

Publication number Publication date
KR100782246B1 (ko) 2007-12-05
KR20060061399A (ko) 2006-06-07
AR046043A1 (es) 2005-11-23
CA2540062A1 (fr) 2005-04-14
EP1677779B1 (fr) 2008-09-24
CN1859902A (zh) 2006-11-08
CN100453075C (zh) 2009-01-21
ES2314457T3 (es) 2009-03-16
GEP20084546B (en) 2008-11-25
BRPI0415043A (pt) 2006-12-12
US20100056564A1 (en) 2010-03-04
DE602004016762D1 (de) 2008-11-06
CY1108388T1 (el) 2014-02-12
MY137953A (en) 2009-04-30
NZ545988A (en) 2008-11-28
FR2860436B1 (fr) 2006-01-20
WO2005032533A1 (fr) 2005-04-14
EA200600657A1 (ru) 2006-08-25
UA80220C2 (en) 2007-08-27
AU2004277734B2 (en) 2007-05-24
EA009418B1 (ru) 2007-12-28
US20070054934A1 (en) 2007-03-08
HK1093900A1 (zh) 2007-03-16
JP2007507475A (ja) 2007-03-29
SI1677779T1 (sl) 2009-02-28
PT1677779E (pt) 2008-10-23
AU2004277734A1 (en) 2005-04-14
EP1677779A1 (fr) 2006-07-12
MA28081A1 (fr) 2006-08-01
HRP20080546T3 (hr) 2009-01-31
AU2004277734B8 (en) 2005-04-14
PL1677779T3 (pl) 2009-02-27
DK1677779T3 (da) 2009-01-05
MXPA06003713A (es) 2006-06-14
FR2860436A1 (fr) 2005-04-08
ATE409033T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
NO20091976L (no) Nye forbindelser
BRPI0414599A (pt) pirrol-indóis substituìdos
SE0303596L (sv) Ny banprodukt av metall
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
ATE532768T1 (de) Pyridylinhibitoren der hedgehog-signalvermittlung
FI20020334A0 (fi) Luonnon syklodekstriinin uuden kompleksit
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
SE0301653D0 (sv) Novel compounds
DE602004017486D1 (de) Substituierte heteroarylbenzofuransäuren
EP1692287A4 (en) BACTERIAL VIRULENT FACTORS AND USES THEREOF
JP2006502186A5 (ja) β-グルカンの使用
NO20044898L (no) Nye etonogestrel estere
NO20056161L (no) Formuleringer for behandling av artrittilstander
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
NO20055741L (no) Nye kjemiske forbindelser
UY28344A1 (es) Nuevos compuestos
EA201000566A1 (ru) Гетероциклические сетр ингибиторы
DE502006005053D1 (de) Spritzbare akustikmassen
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
NO20061944L (no) Ny assosiasjon av et antiaterotrombotisk middel og et antiplateaggregerede middel
MX2007003398A (es) Sulfonamidas y sus usos.
DK1572217T3 (da) Kombinationsmedikament af R,R-formoterol og ciclesonid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application